Overview

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in patients with isocitrate dehydrogenase (IDH) mutant glioma.
Phase:
Early Phase 1
Details
Lead Sponsor:
Robert Bok, MD, PhD
Collaborator:
National Cancer Institute (NCI)